We are live on ! Find out more
CGEM icon

Cullinan Therapeutics

66 hedge funds and large institutions have $762M invested in Cullinan Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 32 increasing their positions, 12 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 12

99% more capital inflows, than outflows

Capital inflows: $88.1M | Capital outflows: $44.3M

3.66% more ownership

Funds ownership: 74.12% → 77.77% (+3.7%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7% less funds holding

Funds holding: 71 → 66 (-5)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

Holders
66
Holders Change
-5
Holders Change %
-7.04%
% of All Funds
1.15%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
7
Increased
32
Reduced
12
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CGEM Hedge Fund Activity: Q3 2021 in Review

66 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q3 2021, worth a combined $762M — down 8% from $829M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CGEM and 7 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 32 added.

The largest buyer was Vanguard Group, adding an estimated $30.1M. The largest seller was Ikarian Capital, exiting entirely with an estimated $7.61M sold.

  • 66 institutional investors held Cullinan Therapeutics (CGEM) as of Q3 2021, down from 71 in Q2 2021.
  • Funds reported $762M of Cullinan Therapeutics stock for Q3 2021, down 8% quarter-over-quarter.
  • 7 funds opened new Cullinan Therapeutics positions in Q3 2021 and 12 closed out, a net change of -5 holders.
  • The largest Cullinan Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $30.1M added.
  • The largest Cullinan Therapeutics seller in Q3 2021 was Ikarian Capital, an estimated $7.61M sold.

Based on aggregated 13F filings for Q3 2021.